secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000885725-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q4 revenue $4.56B (+22% YoY) beats guidance; adj EPS $0.70; FY25 organic guide 10-12%
--------------------------------------------------------------------------------

- Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.
- Full year 2024 net sales $16.747B (+17.6% reported); GAAP EPS $1.25, adjusted EPS $2.51.
- Cardiovascular segment grew 28.8% reported; U.S. sales up 30.7%.
- Guidance: Q1 2025 adj EPS $0.66-0.68, FY 2025 adj EPS $2.80-2.87; organic growth 10-12% for FY.
- Completed acquisitions of Axonics and Cortex; announced deals for Bolt Medical and Intera Oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/0000885725-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/bsx-20250205.htm
  HTML page:      https://secwatch.observer/filing/0000885725-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer